Summit Therapeutics Inc.
SMMT
Classifica tra le azioni
#1684
Summit Therapeutics Inc. is a biopharmaceutical firm dedicated to discovering,... Summit Therapeutics Inc. is a biopharmaceutical firm dedicated to discovering, developing, and commercializing therapeutic solutions, primarily targeting infectious diseases across the United States and Latin America. The company's clinical development pipeline is heavily concentrated on therapies for Clostridioides difficile infection (CDI). Its flagship product candidate, ridinilazole, is an orally administered small molecule antibiotic currently advancing through Phase III clinical trials as a treatment for CDI. Beyond its lead asset, Summit Therapeutics is also progressing SMT-738, designed to combat multidrug-resistant infections, notably carbapenem-resistant Enterobacteriaceae (CRE). Additionally, its DDS-04 series represents a potential therapeutic avenue for various infections caused by the Enterobacteriaceae family of bacteria. Established in 2003, the company maintains its headquarters in Cambridge, Massachusetts.
Prezzo delle azioni
$15.60
Capitalizzazione di mercato
$12.44B
Variazione (1 giorno)
-1.45%
Variazione (1 anno)
-18.58%
Paese
US
Scambia Summit Therapeutics Inc. (SMMT)
Categoria
Healthcare
Ricavi di Summit Therapeutics Inc. (SMMT)
Ricavi nel Jun 2026 TTM: 0.00
Secondo gli ultimi rapporti finanziari di Summit Therapeutics Inc., i ricavi attuali dell'azienda (TTM) sono pari a 0.00. Nel 2024, l'azienda ha registrato ricavi di 0.00 uguale a i ricavi dell'anno 2023, che erano pari a 0.00. I ricavi rappresentano l'importo totale generato dalla vendita di beni o servizi. A differenza degli utili, le spese non vengono detratte.
Storico dei ricavi per Summit Therapeutics Inc. da 2004 a 2026
Ricavi alla fine di ogni anno
| Anno | Ricavi | Cambia |
|---|---|---|
| 2026 (TTM) | 0.00 | 0.00% |
| 2025 | 0.00 | 0.00% |
| 2024 | 0.00 | 0.00% |
| 2023 | 0.00 | -100.00% |
| 2022 | $583.19K | -56.40% |
| 2021 | $1.34M | 112.71% |
| 2020 | $628.88K | -22.49% |
| 2019 | $811.40K | -95.97% |
| 2018 | $20.12M | 572.62% |
| 2017 | $2.99M | 63.98% |
| 2016 | $1.82M | -35.84% |
| 2015 | $2.84M | -6.20% |
| 2014 | $3.03M | 0.91% |
| 2013 | $3.00M | 70.70% |
| 2012 | $1.76M | 49.07% |
| 2011 | $1.18M | 143.56% |
| 2010 | $484.72K | 26.56% |
| 2009 | $383.00K | -96.80% |
| 2008 | $11.98M | 201.54% |
| 2007 | $3.97M | 135.85% |
| 2006 | $1.68M | 320.18% |
| 2005 | $400.93K | 11,998.27% |
| 2004 | $3.31K | 0.00% |
Ricavi di aziende simili o concorrenti
| Azienda | Ricavi | Differenza nei ricavi | Il paese |
|---|---|---|---|
| $12.62B | - |
US
|
|
| $2.23B | - |
US
|
|
| $15.74B | - |
AU
|
|
| $6.02B | - |
NL
|
|
| $10.11B | - |
BE
|
